Supplementary Material

Contents:

Appendix 1 A flow chart to demonstrate how T-score site was chosen, and how osteoporosis,
osteopenia (low bone mass) and normal BMD were categorised2
Appendix 2 How zoledronate and denosumab were considered in the medication gap
analysis2
Appendix 3 Reasons given by participants for not having a DXA scan3
Appendix 4 Comparing age, sex, MDS-UPDRS Part III and CFS Scores of those who did and did
not have a DXA scan
Appendix 5 Frequency of Bone Protective Medications in our study population4
Appendix 6 FRAX-derived probabilities of fracture, and NOGG risk categorisation, before and
after the inclusion of Femoral Neck BMD in the FRAX algorithm4
Appendix 7 Comparing those who did and did not experience recurrent falls5
Appendix 8 FRAX-derived probabilities of fracture without the inclusion of femoral neck BMD,
before and after adjustment for recurrent falls5
Appendix 9 FRAX-derived probabilities of fracture with the inclusion of femoral neck BMD,
before and after adjustment for recurrent falls5

Appendix 1 A flow chart to demonstrate how T-score site was chosen, and how osteoporosis, osteopenia (low bone mass) and normal BMD were categorised.



Appendix 2 How zoledronate and denosumab were considered in the medication gap analysis.

Participants were considered 'on treatment' if anabolic or anti-resorptive treatments were started and not discontinued before the baseline visit. Treatment with Zoledronate was considered to be discontinued if participants had their most recent intravenous infusion more than 18 months before the baseline visit. Denosumab treatment was considered to be discontinued if participants had their most recent injection more than 8 months before the baseline visit.

Reason	Ν	Percentage
Back pain	1	4%
Burden	1	4%
DNA/Cancelled	5	19%
Housebound or bedbound	3	11%
Mobility	2	7%
No specific reason given	9	33%
Additional travel	4	15%
Uncertainty about scan benefits	1	4%
Withdrawn from PRIME-RCT	1	4%
Total	27	100%

Appendix 3 Reasons given by participants for not having a DXA scan

Appendix 4 Comparing *age, sex, MDS-UPDRS Part III and CFS Scores of* those who did and did not have a DXA scan

		DXA Scan	
	No DXA	Available	p-value
Ν	28 (13.1%)	186 (86.9%)	
Age at Visit 1	78.6 (5.8)	73.9 (8.3)	0.005
Gender			
Female	11 (39.3%)	64 (34.4%)	0.614
Male	17 (60.7%)	122 (65.6%)	
MDS-UPDRS Section 3	58.6 (21.9)	40.3 (18.5)	<0.001
Frailty			
CFS < 5	5 (17.9%)	127 (68.3%)	<0.001
CFS ≥ 5	23 (82.1%)	59 (31.7%)	
		1	

Continuous data are described as mean (SD), and compared with t-test Categorical data is described as frequency (Percent%), and compared with Chi Square test Frailty is described as frequency (Percent%), and compared with a z-test of proportions

	_
	Frequency
Total N	182
None	161 (88.5%)
Alendronate	16 (8.8%)
Risedronate	3 (1.6%)
Zoledronate	1 (0.5%)
Denosumab	1 (0.5%)

Appendix 5 Frequency of prescribed Bone Protective Medications in our study population

Appendix 6 FRAX-derived probabilities of fracture, and NOGG risk categorisation, before and after the inclusion of Femoral Neck BMD in the FRAX algorithm

	Femoral Neck BMD Included		
	No	Yes	
Ν	182.0 (50.0%)	182.0 (50.0%)	
FRAX probability of MOF*	16.3 (11.1)	12.7 (9.0)	
FRAX probability of Hip fracture*	8.5 (9.0)	5.0 (6.8)	
NOGG Category*			
Low Risk	73.0 (40.1%)	126.0 (69.2%)	
Intermediated Risk - below IT ⁺	57.0 (31.3%)	0.0 (0.0%)	
Intermediate Risk-above IT‡	14.0 (7.7%)	0.0 (0.0%)	
High Risk	18.0 (9.9%)	23.0 (12.6%)	
Very High Risk	20.0 (11.0%)	33.0 (18.1%)	
Continuous data are described as me	an (Standard Deviation)		

Categorical data is described as frequency (Percent%)

* PD was included as rheumatoid arthritis

+ Intermediate Risk, but below the intervention threshold

‡ Intermediate Risk, but above the intervention threshold

No Recurrent Falls	Recurrent Falls	p-value
108 (59.3%)	74 (40.7%)	
73.8 (8.1)	73.9 (8.5)	0.887
35 (32.4%)	28 (37.8%)	0.449
73 (67.6%)	46 (62.2%)	
36.2 (18.3)	46.1 (17.1)	<0.001
	No Recurrent Falls 108 (59.3%) 73.8 (8.1) 35 (32.4%) 73 (67.6%) 36.2 (18.3)	No Recurrent Falls Recurrent Falls 108 (59.3%) 74 (40.7%) 73.8 (8.1) 73.9 (8.5) 35 (32.4%) 28 (37.8%) 73 (67.6%) 46 (62.2%) 36.2 (18.3) 46.1 (17.1)

Appendix 7 Comparing those who did and did not experience recurrent falls

Continuous data are described as mean (SD), and compared using a t-test Categorical data is described as frequency (Percent%), and compared using a Chi square test

Appendix 8 FRAX-derived probabilities of fracture without the inclusion of femoral neck BMD, before and after adjustment for recurrent falls

	No Falls Adjustment	Falls Adjustment Applied*
Ν	182 (50.0%)	182 (50.0%)
FRAX Score for MOF	16.3 (11.1)	18.3 (12.8)
FRAX Score for Hip	8.5 (9.0)	9.6 (10.1)

Continuous data are described as mean (SD)

*Falls adjustment is a 30% increase in FRAX probability applied where people experienced recurrent falls (2 or more falls over the previous year) – there were 74 recurrent fallers in the study population

Appendix 9 FRAX-derived probabilities of fracture with the inclusion of femoral neck BMD, before and after adjustment for recurrent falls

	No Falls Adjustment	Falls Adjustment Applied*
N	182.0 (50.0%)	182.0 (50.0%)
FRAX Score for MOF	12.7 (9.0)	14.2 (9.9)
FRAX Score for Hip	5.0 (6.8)	5.5 (7.2)

Continuous data are described as mean (SD)

*Falls adjustment is a 30% increase in FRAX probability applied where people experienced recurrent falls (2 or more falls over the previous year) – there were 74 recurrent fallers in the study population